FluMist Safe for Immunocompromised Children
Drug Discovery & Development - May 11, 2009
Data suggest that FluMist (Influenza Vaccine Live, Intranasal) has an acceptable safety profile among mild to moderately immunocompromised children with cancer. The immune systems of children with cancer can be weakened due to cancer treatments, making them vulnerable to influenza or other infections. The small multi-center, randomized, double-blind pilot study compared FluMist to placebo in 20 children, five to 17 years of age. The results, along with data from 10 other MedImmunesponsored, influenza-related studies, were presented at the 2009 Pediatric Academic Societies (PAS) annual meeting in Baltimore, MD.
In our pilot study, immunocompromised children with cancer who received FluMist had no related serious adverse events, explained Pat Flynn M.D., director, clinical research, infectious diseases, St. Jude Children's Research Hospital. We believe these data are promising and add to the extensive body of evidence supporting the overall safety of FluMist in the population for whom it is approved. A larger study will help us confirm the safe use of FluMist in immunocomprised patients. The value of this type of research is even more apparent today as we all consider how best to protect all of our patients against the threat of emerging, new influenza viruses.
Date: May 5, 2009